EP2701728B1 - Formulation comprenant crh et l'alpha-2-macroglobuline - Google Patents

Formulation comprenant crh et l'alpha-2-macroglobuline Download PDF

Info

Publication number
EP2701728B1
EP2701728B1 EP13709511.3A EP13709511A EP2701728B1 EP 2701728 B1 EP2701728 B1 EP 2701728B1 EP 13709511 A EP13709511 A EP 13709511A EP 2701728 B1 EP2701728 B1 EP 2701728B1
Authority
EP
European Patent Office
Prior art keywords
crh
formulation
serum
alpha
macroglobulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP13709511.3A
Other languages
German (de)
English (en)
Other versions
EP2701728A1 (fr
Inventor
Deirdre.P. MCINTOSH
David.J. SHOTTON
Syed. Ebadat. HAQ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aimsco Ltd
Original Assignee
Aimsco Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1211247.0A external-priority patent/GB201211247D0/en
Application filed by Aimsco Ltd filed Critical Aimsco Ltd
Publication of EP2701728A1 publication Critical patent/EP2701728A1/fr
Application granted granted Critical
Publication of EP2701728B1 publication Critical patent/EP2701728B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2228—Corticotropin releasing factor [CRF] (Urotensin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/017—Hydrolysed proteins; Derivatives thereof from animals from blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Definitions

  • the present invention relates to a formulation having improved stability/ efficacy.
  • the formulation is particularly suitable for treatment of various disorders.
  • the invention also relates to a method of producing the formulation.
  • WO 2006/021814 describes a serum composition comprising corticotropin releasing factor (CRF).
  • WO 2006/021814 also describes the use of CRF for treating a number of disorders, in particular multiple sclerosis and inflammatory disorders such as rheumatoid arthritis; optic neuritis; motor neuron disease; autoimmune diseases; axonal or nerve damage; and cancers.
  • disorders include myelomas, melanomas and lymphomas.
  • Other disorders include cardiovascular diseases; and neural disorders, both demyelinating and non-demyelinating.
  • Examples of particular disorders which may be treated with CRF include cerebrovascular ischemic disease; Alzheimer's disease; Huntingdon's chorea; mixed connective tissue diseases; scleroderma; anaphylaxis; septic shock; carditis and endocarditis; wound healing; contact dermatitis; occupational lung diseases; glomerulonephritis; transplant rejection; temporal arteritis; vasculitic diseases; hepatitis; and burns.
  • Particular non-demyelinating disorders which may be treated include multiple system atrophy; epilepsy; muscular dystrophy; schizophrenia; bipolar disorder; depression; channelopathies; myasthenia gravis; pain due to malignant neoplasia; chronic fatigue syndrome; fibromyositis; irritable bowel syndrome; work related upper limb disorder; cluster headache; migraine; and chronic daily headache.
  • Particular demyelinating disorders which may be treated include infections of the nervous system; nerve entrapment and focal injury; traumatic spinal cord injury; brachial plexopathy (idiopathic and traumatic, brachial neuritis, parsonage turner syndrome, neuralgic amyotrophy); radiculopathy; channelopathies; and tic douloureux.
  • Particular autoimmune disorders which may be treated include lupus; psoriasis; eczema; thyroiditis; and polymyositis.
  • Particular peripheral neuropathy of axonal and demyelinating type which may be treated include hereditary motor and sensor neuropathy of all types; Charcot-Marie-Tooth disease (CMT) types CMT1A, CMT1 B, CMT2, CMT3 (Dejerine Sottas disease), CMT4 (Types A, B, C and D), X-linked Charcot-Marie-Tooth disease (CMTX); Hereditary Neuropathy with liability to pressure palsies (HNPP), also called Tomaculous neuropathy; Hereditary Motor and Sensory Neuropathy with Deafness - Lom (HMSNL); Proximal Hereditary Motor and Sensory Neuropathy/Neuronopathy (HMSNP); Hereditary Neuralgic Amyotrophy; Hereditary Sensory and Autonomic Neuropathies (HSAN1, HSAN2, HSAN3 (also called
  • CRF chronic inflammatory demyelinating polyneuropathy
  • CIDP chronic inflammatory demyelinating polyneuropathy
  • PF-4 platelet factor-4
  • CRF corticotropin releasing hormone
  • corticoliberin corticotropin releasing hormone
  • CRH formulations Prior administration to a patient, the CRH protein has a limited effective biological half-life - by way of example, the CRH protein has a very low effective plasma half-life (approximately 4 minutes), and thus a low bioavailability/ efficacy, relying on a pulsatile stimulus.
  • CRH formulations have limited stability, and thus sub-optimal efficacy. There is therefore a need for a CRH formulation having improved stability and thus a longer effective therapeutic window of efficacy.
  • the present invention addresses one or more of the above needs by providing a stabilised CRH formulation which demonstrates an extended effective biological half-life (e.g. persistence) in the body.
  • Therapeutic uses of such stabilised CRH are also provided for prevention or treatment of one or more diseases (including, but not limited to, said hereinbefore listed disorders).
  • the present invention provides a formulation comprising a stabilised complex of CRH and alpha-2 macroglobulin, wherein the latter is believed to protect CRH in vivo.
  • the alpha-2 macroglobulin is present in the formulation of the invention at a concentration of more than 50,000 picograms per millilitre, for example between 100,000 and 150,000 picograms per millilitre, or between 110,000 and 130,000 picograms per millilitre.
  • the present invention provides alpha-2 macroglobulin in a preferred amount for complexing with CRH.
  • the CRH may be present in the formulation of the invention at a concentration of between 80 picograms per millilitre (pg/ml) and 120 pg/ml, for example between 90 and 110 pg/ml.
  • the present invention provides CRH in an amount that is preferred for complexing with alpha-2 macroglobulin.
  • the alpha-2 macroglobulin may be present in the formulation of the invention at a concentration of between 100,000 and 150,000 picograms per millilitre, and the CRH may be present at a concentration of between 80 picograms per millilitre (pg/ml) and 120 pg/ml, for example between 90 and 110 pg/ml.
  • the alpha-2 macroglobulin may be present in the formulation of the invention at a concentration of between 110,000 and 130,000 picograms per millilitre, and the CRH may be present at a concentration of between 80 picograms per millilitre (pg/ml) and 120 pg/ml, for example between 90 and 110 pg/ml.
  • the formulation of the invention may further comprise CRH binding protein (CRH-BP).
  • CRH-BP CRH binding protein
  • the CRH-BP may be present at a concentration of between 30 and 60 picograms per millilitre (pg/ml), for example between 40 and 50 pg/ml.
  • the stabilised CRH formulation of the present invention is prepared by a method that comprises: providing isolated blood from an ungulate (e.g. a goat), wherein said ungulate has been immunised with an autoimmune virus, and obtaining serum from the blood ( e.g. by centrifugation); treating the serum to separate the CRH and other active components of interest; diafiltration of the separated serum comprising CRH and other active components of interest, thereby retaining molecules having a molecular weight of at least 10 KDa; filtering to remove molecules having a size greater than 0.2 microns; processing by nanofiltration to remove molecules having a size greater than 35 nanometres; wherein all of the above steps are performed under cooled conditions (e.g.
  • the processed serum is aliquoted into vials, optionally with protein concentration adjustment, to provide a single dose amount. At this stage it may be frozen ( e.g. at minus 22 degrees C) prior to use. In this regard, prior to use, the aliquoted serum is thawed, followed by prompt administration ( e.g. within 6 hours, preferably within 4 hours, preferably within 1 hour, preferably within 5 minutes, preferably within 1 minute) to a patient.
  • prompt administration e.g. within 6 hours, preferably within 4 hours, preferably within 1 hour, preferably within 5 minutes, preferably within 1 minute
  • the autoimmune virus may be HIV or SIV, which may be HIV 3b; the autoimmune virus may be in the form of a lysate or a heat-killed virus.
  • serum is defined as that component of the blood from which the blood cells have been removed, e.g. by centrifugation.
  • WO 2006/021814 which is hereby incorporated in its entirety by reference thereto, may be employed, though with the inclusion of one or more additional steps selected from (i) a nanofiltration step; (ii) avoidance of multiple freeze-thaw steps and/ or minimising ambient temperature exposure; and/ or (iii) a mixing/ agitation step (to enhance CRH: alpha-2 macroglobulin complex formation).
  • the present invention provides a method of manufacturing a stabilised complex of CRH and alpha-2 macroglobulin, the method comprising:
  • Said microfiltration step may follow an ammonium sulphate precipitation plus (PBS) buffer dialysis step to retain molecules of, for example, at least 10 KDa.
  • PBS ammonium sulphate precipitation plus
  • Said nanofiltration step may be carried out using a 35 nanometre filter, which may be a 35 nanometre hollow fibre filter.
  • ambient temperature e.g. room temperature, 22 degrees C
  • cold trays ensuring a maximum temperature of less than 22 degrees C, or less than 10 degrees C, or less than 7 degrees C, or less than 5 degrees C
  • the composition may be kept at a constant temperature below 22 degrees C, e.g. at less than 10 degrees C, or less than 7 degrees C, or less than 5 degrees C.
  • the method is carried out as a continuous process, avoiding any freezing steps prior to storage. For example, no freezing step is employed between the filtration step (e.g.
  • micro- and/or nanofiltration and final aliquoting into vials (optionally with adjustment of protein concentration).
  • no freezing step is carried out once the serum has been treated to separate the CRH and other components of interest, e.g. using ammonium sulphate.
  • One or more agitation steps may be carried out during the method; these agitation steps may use cold trays.
  • the method may comprise a final step (e.g. after the micro-/ nano-filtration step and any protein concentration adjustment step) of freezing for subsequent storage.
  • the hyperimmune serum is not frozen prior to micro- and/or nano-filtration.
  • the present inventors believe that the bioactive molecules within the composition comprising CRH are prone to undesirable aggregation upon freezing and thus this step should not be performed more than once prior to use. Thus, multiple freezing-thawing steps should be avoided as they are believed to result in inactivation of key bioactive molecules within the CRH composition and/or lead to removal thereof during subsequent filtration.
  • the CRH formulation of the present invention may be prepared from first principles based on commercially available components (including recombinantly prepared components).
  • the two principal components of the hereindescribed formulation may have a ratio of 4:1 CRH:alpha-2 macroglobulin, 2:1 CRH:alpha-2 macroglobulin, 1:1 CRH:alpha-2 macroglobulin, or combinations thereof.
  • the predominant complexed form of CRH: alpha-2 macroglobulin is a macromolecular quaternary complex (i.e. 4:1).
  • the CRH and alpha-2 macroglobulin components may be complexed together via non-covalent bonds such as one or more of hydrogen bonds, ionic bonds, van der Waals forces, and hydrophobic interactions.
  • concentrations typically refer to the concentrations obtained during the manufacture process such as immediately prior aliquoting and optional freezing for subsequent storage (optionally including any protein concentration adjustment) that yields the ready-to-use formulation (typically having a concentration of 4-5 milligrams protein per millilitre).
  • the CRH may be human or non-human.
  • the CRH may be an ungulate CRH such as horse, zebra, donkey, cattle, bison, goat, pig, moose, elk, deer, antelope or gazelle.
  • the CRH is not ovine CRH.
  • the CRH is caprine CRH.
  • Corticotropin releasing hormone also known as corticoliberin
  • corticoliberin is a 41 residue peptide originally isolated from ovine hypothalamus based on its ability to stimulate the hypothalamic-pituitary adrenal axis from cultured anterior pituitary cells.
  • CRH is the principal neuroregulator of the basal and stress-induced secretion of ACTH, ⁇ -endorphin, and other pro-opiomelanocortin related peptides from the paraventricular nucleus of the anterior pituitary gland.
  • CRH-R1 is a 415 amino acid protein that shows sequence homology across different species (human, mouse and rat).
  • CRH-binding protein represents the smallest receptor at 322 amino acids, and acts as an inhibitor of free CRH.
  • CRH-R1 and CRH-R2 are both ubiquitously expressed on the cell surface of the hypothalamus, cerebellum, cortex, amygdala, subcortex, immune cells, gut and skin.
  • CRH-BP is found predominantly in the liver, placenta and brain. Importantly there appears to be no significant overlap in distribution of the said receptors. This likely reflects differing functional roles. An example of this is seen during pregnancy were elevation in peripheral CRH is regulated by an elevation in secreted levels of CRH binding protein. The overall effect of this is to prevent an elevation in peripheral circulating levels of glucocorticoids during pregnancy.
  • Several forms of CRH have been identified in nature, they include a high molecular weight form 194 amino acids Mw ⁇ 30,000, a Mw -18,000, Mw ⁇ 7,500 and the 41 amino acid residue. All three forms are biologically active and able to stimulate ACTH release.
  • Alpha-2-macroglobulin also known as a2M, is a large plasma protein found in blood. It is produced by the liver and is the largest major non-immunoglobulin protein in plasma. A2M is synthesized primarily by the liver and is also produced locally by macrophages fibroblasts and adrenocortical cells. Alpha-2-macroglobulin acts as an anti-protease and is able to inactivate an enormous variety of proteinases. It also functions as a carrier protein binding to numerous growth factors and cytokines.
  • transferrin where a2M regulates the binding of to the surface receptor
  • a2M regulates the binding of to the surface receptor
  • bFGF basic fibroblast growth factor
  • PDGF platelet derived growth factor
  • NGF nerve growth factor
  • IL-1 ⁇ interleukin-1 ⁇
  • IL-6 interleukin-6
  • TGF-1 ⁇ transforming growth factor
  • insulin and modify their biological activity.
  • Human a2M is composed of four identical subunits bound together by-S-S-bonds. The principal mechanism by which a2M inhibits proteases is through steric hindrance.
  • the mechanism involves protease cleavage of the thiol 35 amino acid bait region, a segment of the molecule, which is particularly susceptible to proteolytic cleavage, which initiates conformational change such that a2M collapses about the protease thus resulting in its inhibition.
  • the active site of the protease is sterically shielded, thus substantially decreasing access to protein substrates including those that are bound to active a2M. Decreases in a2M been associated with a variety of diseases, or example common variant (29.5%) polymorphism of a2M needs to increase the risk of Alzheimer's disease.
  • Stabilisation of CRH by binding to alpha-2 macroglobulin, and the attendant enhanced effective biological half-life is one effect of formulations of the present invention.
  • Said stability provides an enhanced (longer) plasma half-life - by way of example, the stabilised complex of the present invention has a half-life of at least 24 hours.
  • the stabilised complex of the invention may be employed in combination with one or more other stabilisers, such as fibronectin or albumin. Additionally or alternatively, the stabilised complex of the invention may be employed in combination with a pro-opiomelanocortin (POMC) peptide.
  • POMC pro-opiomelanocortin
  • POMC may be present in the formulation at a range of between 140 picomoles per litre (pmol/l) and 200 pmol/l.
  • the invention provides a stabilised CRH formulation having component proportions as defined herein.
  • the formulation may have between 110,000 and 130,000 picograms per millilitre (pg/ml) of alpha-2 macroglobulin, between 60 pg/ml and 120 pg/ml of CRH, and optionally between 140 pmol/l and 200 pmol/l of POMC.
  • alpha-2 macroglobulin inhibits subtilisin serine endopeptidases (pro-hormone convertases), which may otherwise exert deleterious effects on POMC prior to administration.
  • POMC prohormone convertase 1
  • PC2 prohormone convertase 2
  • CPE carboxypeptidase E
  • PAM peptidyl alpha-amidating monooxygenase
  • N-AT N-acetyltransferase
  • PRCP prolylcarboxypeptidase
  • Human POMC peptide is described in detail in entry 176830 of OMIM (online mendelian inheritance in man, accessible through http://www.ncbi.nlm.nih.qovA).
  • the nucleotide and amino acid sequence of human POMC is also known, and has GENBANK accession number BC065832.
  • Human POMC gives rise to a glycosylated protein precursor having a molecular weight of 31 kDa.
  • a POMC peptide is meant any peptide having a corresponding sequence, structure, or function. It will be apparent to the skilled person that the canonical nucleotide and/or amino acid sequences given for human POMC in the GENBANK entry referenced above may be varied to a certain degree without affecting the structure or function of the peptide. In particular, allelic variants and functional mutants are included within this definition. Mutants may include conservative amino acid substitutions.
  • a POMC peptide refers to any peptide acting as a precursor to at least one form of MSH, ACTH, at least one form of lipotrophin (LPH), ⁇ endorphin, met-enkephalin and leu-enkephalin; and preferably all of ⁇ , ⁇ , and ⁇ MSH; ACTH; ⁇ and ⁇ LPH; and ⁇ endorphin, met- enkephalin and leu-enkephalin.
  • LPH lipotrophin
  • the POMC peptide may be human or non-human POMC.
  • the POMC peptide is an ungulate POMC such as horse, zebra, donkey, cattle, bison, goat, pig, moose, elk, deer, antelope or gazelle.
  • the POMC peptide is not a rodent (e.g. mouse or rat) POMC peptide.
  • Administration of a POMC peptide has a self-sustaining effect, in that administration of an initial amount of POMC peptide leads to endogenous production of POMC in the patient; thus, an initial administration of a low level of POMC has a significant effect on the patient.
  • the formulation of the invention selectively increases the enzymatic degradation of POMC in vivo.
  • the formulation of the invention increases the release of POMC-derived peptides such as ACTH, alpha-MSH, beta-MSH, CLIP, Lipotrophin-gamma, met-enkephalins and beta-endorphins. Longer-term administration of the formulation typically leads to a sustainable increase in POMC-derived peptides in a patient.
  • the formulation of the invention typically possesses a reduced amount of immunoglobulin component.
  • the associated method of the present invention provides a formulation in which the immunoglobulin component has been minimised - for example, in said formulation, the immunoglobulin component has been minimised so that the formulation contains less than 4.5 mg/ml, for example less than 4 mg/ml or less than 3.9 mg/ml.
  • a reduced immunoglobulin component is preferred as this helps to minimise a host immune response against said component (notably against any IgG component).
  • concentrations typically refer to the concentrations obtained during the manufacture process such as immediately prior to aliquoting and optional freezing for subsequent storage (optionally including any protein concentration adjustment) that yields the ready-to-use formulation.
  • the stabilised complex of the invention acts to enhance the central CRH-1 regulatory response. This results in optimisation of key anti-inflammatory cytokines and abrogation of certain pro-inflammatory cytokines related to the Th1-mediated response.
  • CRH CRH-induced CRH
  • CRH can therefore be administered at a low concentration to a patient.
  • the stabilised complex of the invention also protects CRH from proteolytic degradation by proteases and accordingly administration of the stabilised complex of the invention provides slow release of CRH in the circulation and a significant increase in CRH levels.
  • the stabilised complex of the invention leads to persistent, elevated levels of CRH in vivo for at least 12 hours following administration, for at least 24 hours following administration, or for at least 48 hours following administration.
  • Administration of the stabilised complex of the invention may lead to an in vivo increase in CRH concentration of between 25% and 50% from patient baseline CRH levels at 24 hours from administration, and an in vivo increase of between 75% and 100% from patient baseline CRH levels at 48 hours from administration.
  • the formulation of the invention selectively up-regulates the CRH-1 receptor both centrally and peripherally in key target issues and enhances the central CRH-1 regulatory response, while also leading to selective down-regulation of CRH-2 specific receptors and up-regulation of CRH-binding protein in tissues such as the adrenal cortex. It is believed by the inventors that administration of the formulation will thus lead to optimisation of key inflammatory cytokines and down-regulation of certain pro-inflammatory cytokines related to the Th-1 mediated response, through targeting leucocytes and macrophages.
  • the combined net effect of all of the above is an anti-inflammatory, reparative and fundamental immunomodulatory therapeutic that works within homeostatic constraints.
  • the unique targeting and accessibility of the stabilised complex of the invention explains its versatility in a wide range of diseases.
  • the present invention provides a stabilised CRH formulation that works within homeostatic constraints following in vivo administration.
  • the present invention accordingly further provides a formulation for use in prevention or treatment of one or more diseases selected from systemic sclerosis (SSc), multiple sclerosis and inflammatory disorders such as rheumatoid arthritis; optic neuritis; motor neuron disease; autoimmune diseases; axonal or nerve damage; and cancers (including myelomas, melanomas and lymphomas); cardiovascular diseases; neural disorders, both demyelinating and non-demyelinating; cerebrovascular ischemic disease; Alzheimer's disease; Parkinson's disease; Huntingdon's chorea; mixed connective tissue diseases; scleroderma; anaphylaxis; septic shock; carditis and endocarditis; wound healing; contact dermatitis; occupational lung diseases; glomerulonephritis; transplant rejection; temporal arteritis; vasculitic diseases; hepatitis (in particular hepatitis C); burns; multiple system atrophy; epilepsy; muscular dystrophy; schizophrenia; bipolar disorder; depression;
  • the formulation of the present invention may take the form of a pharmaceutical composition.
  • the invention accordingly provides a pharmaceutical composition comprising the stabilised complex of the invention, and the use thereof in preventing or treating of one or more of the above-mentioned diseases.
  • Administration of the formulation of the invention may be accomplished orally or parenterally.
  • Methods of parenteral delivery include topical, intra-arterial, intramuscular, subcutaneous, intramedullary, intrathecal, intra-ventricular, intravenous, intraperitoneal, or intranasal administration.
  • the formulation of the invention may comprise suitable pharmaceutically acceptable carriers comprising excipients and other components which facilitate processing of the active compounds into preparations suitable for pharmaceutical administration.
  • Oral formulations may include pharmaceutically acceptable carriers known in the art in dosages suitable for oral administration. Such carriers enable the compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like suitable for ingestion by the subject.
  • Formulation for oral use can be obtained through combination of active compounds with a solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable additional compounds if desired to obtain tablets or dragee cores.
  • Suitable excipients include carbohydrate or protein fillers such as sugars, including lactose, sucrose, mannitol, sorbitol; starch from corn, wheat, rice, potato, or other plants; cellulose such as methylceilulose, hydroxypropylmethylcellulose, or sodium carboxymethylcellulose; and gums including arabic and tragacanth; as well as proteins such as gelatin and collagen.
  • disintegrating or solubilising agents may be added, such as cross linked polyvinyl pyrrolidone, agar, alginic acid, or a salt thereof.
  • Dragee cores can be provided with suitable coatings such as concentrated sugar solutions, which may also contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for product identification or to characterise the quantity of active compound.
  • suitable coatings such as concentrated sugar solutions, which may also contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures.
  • Dyestuffs or pigments may be added to the tablets or dragee coatings for product identification or to characterise the quantity of active compound.
  • Formulations for oral use include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a coating such as glycerol or sorbitol.
  • Push-fit capsules can contain active ingredients mixed with a filler or binders such as lactose or starches, lubricants such as talc or magnesium stearate, and, optionally stabilisers.
  • the active compounds can be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycol with or without stabilisers.
  • Formulations for parenteral administration include aqueous solutions of active compounds.
  • the formulations of the invention may take the form of aqueous solutions, preferably in physiologically compatible buffers such as Hank's solution, Ringer's solution, or physiologically buffered saline.
  • Aqueous suspension injections can contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran.
  • suspensions of the active compounds can be prepared as appropriate oily injection suspensions.
  • Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes.
  • the suspension can also contain suitable stabilisers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.
  • penetrants appropriate to the particular barrier to be permeated may be used in the formulation.
  • the formulations of the present invention can be manufactured substantially in accordance with standard manufacturing procedures known in the art.
  • the formulation may also comprise one or more peptide regulatory or releasing factors, which may induce a cascade of release of further peptides by a variety of cells in the patient.
  • additional factors are typically provided from the same animal species as the CRH. Suitable factors include ⁇ - HLA, TGF- ⁇ , and IL-10, among others.
  • the formulation may comprise one or more of vasopressin, beta endorphin, and an enkephalin.
  • the formulation may comprise CRH binding protein, CRH-BP. This binds CRH and acts as a reservoir for subsequent release of CRH to the patient.
  • the present invention also provides a formulation for use in a method of treatment for a disease selected from systemic sclerosis (SSc); multiple sclerosis; rheumatoid arthritis; optic neuritis; Parkinson's disease; motor neuron disease; autoimmune diseases including lupus, psoriasis, eczema, thyroiditis, and polymyositis; axonal or nerve damage; cancers, in particular myelomas, melanomas, and lymphomas; neural disorders, both demyelinating and non-demyelinating; inflammatory conditions; obesity; nerve conduction disorders; and sexual dysfunction, in particular erectile dysfunction; the method comprising administering the formulation of the invention to a patient in need thereof.
  • SSc systemic sclerosis
  • multiple sclerosis rheumatoid arthritis
  • optic neuritis
  • Parkinson's disease motor neuron disease
  • autoimmune diseases including lupus, psoriasis, eczema, thyroid
  • administration may be in a dosage of between 0.01 and 10 mg (total protein) per kg (patient), for example between 0.01 and 5 mg/kg, between 0.025 and 2 mg/kg, or between 0.05 and 1 mg/kg.
  • a product suitable for administration to patients may have a total protein concentration of approximately 4 mg/ml.
  • the precise dosage to be administered may be varied depending on such factors as the age, sex and weight of the patient, the method and formulation of administration, as well as the nature and severity of the disorder to be treated. Other factors such as diet, time of administration, condition of the patient, drug combinations, and reaction sensitivity may be taken into account.
  • An effective treatment regimen may be determined by the clinician responsible for the treatment.
  • One or more administrations may be given, and typically the benefits are observed after a series of at least three, five, or more administrations. Repeated administration may be desirable to maintain the beneficial effects of the composition.
  • the treatment may be administered by any effective route, such as by subcutaneous injection, although alternative routes which may be used include intramuscular or intra-lesional injection, oral, aerosol, parenteral, topical or via a suppository.
  • the treatment may be administered as a liquid formulation, although other formulations may be used.
  • the treatment may be mixed with suitable pharmaceutically acceptable carriers, and may be formulated as solids (tablets, pills, capsules, granules, etc) in a suitable composition for oral, topical or parenteral administration.
  • the invention also provides use of the aforementioned formulation in the preparation of a medicament for the treatment of one or more of the diseases recited above.
  • CRH and products containing CRH are very sensitive to proteolytic degradation and suffer from the above-mentioned poor effective half-life following in vivo administration.
  • the stabilized complex of the invention has improved in vivo stability and, in view of said enhanced biological half-life, is able to demonstrate a greater therapeutic efficacy.
  • Hyperimmune ungulate serum is centrifuged to separate any unwanted components, and the method carried out as a continuous process, avoiding any freezing or thawing step(s) prior to final aliquoting. This avoids any aggregation and loss of the CRH component from the formulation.
  • a serum composition comprising CRH was stored at 2 to 8 degrees C (and not frozen) and was diluted at a ratio of 1:2 parts cold PBS, and supersaturated ammonium sulphate was added slowly with constant agitation until a ratio of 47:53 of ammonium sulphate:PBS was reached. This was carried out on a cold tray and the resulting solution was maintained at this temperature for 30 to 60 minutes with constant agitation.
  • the serum solution was then centrifuged in a Beckman J6M/E centrifuge at 3500 rpm for 45 minutes at 4 degrees C. The supernatant was removed and discarded. The precipitated solid material was re-suspended in cold 50% saturated ammonium sulphate:PBS solution and re-centrifuged at 3500 rpm at 4 degrees C for 45 minutes. The supernatant was again discarded and the precipitated solid material re-suspended in ice cold PBS buffer. This solution (the serum component) was then subjected to diafiltration at 4 degrees C against PBS with a molecular weight cut-off of 10,000 Daltons.
  • a two-stage filtration step was then carried out, whereby the solution was filtered through a 0.2 micrometre filter and was then passed through a 35 nanometre hollow fibre filter. Following the filtration step, the solution was adjusted to a protein concentration of between 4 to 5 milligrams per millilitre with ice-cold PBS.
  • Example 2 The stabilised complex provides a persistent, elevated concentration of CRH in vivo
  • the stabilised complex of the invention has been compared with prior art formulations as previously disclosed by applicant.
  • Applicant has disclosed the same basic manufacture protocols in WO 2003/004049 , WO 2003/064472 , WO 2005/056053 , WO 2005/097183 , WO 2006/021814 , and WO 2007/077465 .
  • mice, C57BL/6, ⁇ 25 gm were divided into three groups: one group was administered the stabilised complex of the invention ("Aimspro”); another group was administered a naive caprine serum ( i.e. from a goat that had not been immunised) but which had been otherwise prepared by exactly the same manufacture (including 35 nanometre filtration step) method of the present invention (“Na ⁇ ve serum”); and the third group was administered a composition comprising a CRH formulation prepared by Applicant's prior art basic manufacture protocol ("Prior art CRH formulation").
  • composition of the invention (labelled "Aimspro") provided a steady, sustained increase in CRH concentration within the population over time.
  • CRH concentration was still increasing at the 48-hour point.
  • na ⁇ ve serum Na ⁇ ve serum
  • Prior art CRH formulation Prior art serum formulation
  • CRH-BP CRH binding protein
  • Example 3 Treatment induces protein / peptide expression in patients' sera
  • Mass spectrometry of patients' sera was carried out before and after treatment with the stabilised complex of the invention.
  • the spectra from 2 kDa to 10 kDa are compared, as it is this molecular weight range which is associated with the bioactive peptides of interest discussed above.
  • the results of serum analysis in a first patient are shown pre-treatment ( Figure 3A ) and post-treatment ( Figure 3B ).
  • the results of serum analysis in a second patient are shown pre-treatment ( Figure 3C ) and post-treatment ( Figure 3D ).
  • a comparison of the profiles in the pre- and post-treatment sera of both patients reveals clear differences in the peptide expression in the 2 kDa to 6 kDa region.
  • FIG. 3E An overlapping view of the profiles is also provided ( Figure 3E ).
  • a comparative peptide / protein expression in post-treatment sera of six treated patients is also provided ( Figure 4A to Figure 4F ).
  • Figure 4A to Figure 4F When compared to the pre-treatment expression of the two patients in Figure 3A and Figure 3C , it can be seen in from Figures 4A to 4F that each patient shows increased levels of induced peptide / protein expression particularly in the 4 kD region.
  • Example 3 Evidence for the in vivo activity of the stabilised complex of the invention
  • Figure 6 shows comparative levels of ⁇ endorphin in the serum of patients before and after receiving treatment with the s tabilised complex of the invention. This is compared with levels of ⁇ endorphin in the sera of healthy volunteers. Sera were diluted 1:100 and quantified by an ELISA of sera compared with the product. Data are the mean of three determinations +/standard errors. The data show that treatment increases ⁇ endorphin levels.
  • Example 4 The stabilised complex of the invention leads to a change from pro-inflammatory TH-1 profile to an anti-inflammatory TH-2 cytokine profile in treated patients
  • FIG 7 shows the levels of TGF- ⁇ in the serum of two groups of patients (group 1, shown in Figure 7A ; and group 2, shown in Figure 7B ) before and after treatment with the stabilised complex of the invention.
  • the data show that treatment with the stabilised complex of the invention induces increased concentration of the anti-inflammatory cytokine TGF- ⁇ .
  • Figure 8 shows the levels of IL-4 in the serum of one group of patients before (pre-sera) and after treatment with the stabilised complex of the invention.
  • Figure 10 shows the levels of IFN- ⁇ in the serum of one group of patients before and after treatment. It can be seen that after treatment (post 2nd and post 5th) the levels of IFN- ⁇ are reduced in the patients' sera.
  • Example 5 The stabilised complex of the invention leads to induction of CRH
  • Figure 11 shows firstly, the increased presence of CRH in the stabilised complex of the invention by comparison with a placebo (human albumin at a concentration of 4.5 mg/ml); and secondly, the increase in CRH expression in patients treated with the stabilised complex of the invention by comparison with the non- treated individuals. This latter is evidence for the induction of CRH in patients in response to treatment with the stabilised complex of the invention.
  • a placebo human albumin at a concentration of 4.5 mg/ml
  • Example 6 The stabilised complex of the invention leads to an increase in CRH levels in patients with diffuse systemic sclerosis
  • a double-blind placebo control trial was carried out on patients with diffuse systemic sclerosis.
  • the absolute levels of CRH in micrograms per millilitre) were measured prior to treatment (baseline) and at 26 weeks following treatment.
  • Treatment was carried out in a double-blind placebo control trial, with one group of subjects receiving the stabilised complex of the invention and the other (control) group receiving a placebo (human albumin at a concentration of 4.5 mg/ml).
  • Figure 12 shows a three-fold increase (paired T-test, p ⁇ 0.043) in CRH levels of the patients treated with the stabilised complex of the invention by comparison with those receiving the placebo.
  • Example 7 The stabilised complex of the invention leads to an increase in CRH levels in patients with progressive multiple sclerosis
  • a double-blind placebo control trial was carried out on patients with progressive multiple sclerosis.
  • the absolute levels of CRH (in micrograms per millilitre) were measured prior to treatment (baseline) and at 4 weeks following treatment.
  • Treatment was carried out in a double-blind placebo cross-over trial, with each group of patients receiving a twice-weekly treatment of either the stabilised complex of the invention or a placebo (human albumin at a concentration of 4.5 mg/ml) for four weeks, followed by a 6 week washout period, following which those patients previously receiving the placebo were administered the stabilised complex of the invention twice-weekly for 4 weeks; and those patients previously receiving the stabilised complex of the invention were administered the placebo twice-weekly for 4 weeks.
  • Figure 14 shows that for both groups, there was a significant difference (paired T-test, p ⁇ 0.0023) in levels of CRH following administration of the stabilised complex of the invention, by comparison with the level of CRH following administration of the placebo.
  • Example 8 The stabilised complex of the invention can be used in treating Hepatitis C
  • the subject was a 20 year old female patient with a lifelong history of infection with the Hepatitis C virus (HCV), sub-group type 2b.
  • HCV Hepatitis C virus
  • the subject had previously been treated with interferon (24 month-long regime, unsuccessful) and with pegylated interferon alpha-2a and ribavirin (18-month long regime, unsuccessful). Prior to this study, the subject had received no intervention for the preceding 3 years.
  • Tests confirmed the presence of hepatitis C using HCV antibody enzyme immunoassay and quantitative PCR (1.5*10 6 IU/ml). No jaundice was observed (bilirubin levels of 10 ⁇ mol/litre) and transaminits was detected at a mildly elevated level (aparatate transaminase AST 33 IU/litre, alanine transaminase 58 IU/litre). Further questioning of the subject revealed clinical signs and symptoms including lethargy, weight loss, malaise, insomnia and fatigue.
  • a 1 ml aliquot of the stabilised complex of the invention (4.5 mg/ml concentration) was prepared as described above. This was delivered by intramuscular route on an every other day treatment regimen for an initial six month course.
  • HCV quantitative PCR showed a drop to 150,000 IU/ml.
  • the dosing regimen was then increased to a daily delivery of the stabilised complex of the invention for a further six month course.
  • HCV titres were measured at 90,000 IU/ml, falling to 8,000 IU/ml and then (at the end of the further six months) a negative HCV titre, according to quantitative PCT. Normal liver function tests were also observed at the end of the further six month course.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Claims (15)

  1. Procédé de fabrication d'un complexe stabilisé de CRH et d'alpha-2 macroglobuline, le procédé comprenant :
    (a) la fourniture de sérum hyperimmun provenant d'un ongulé qui a été immunisé avec un virus d'immunodéficience ;
    (b) le fait de soumettre ledit sérum hyperimmun à une étape de microfiltration qui élimine les molécules ayant une taille supérieure à 0,2 micron, en produisant ainsi un sérum microfiltré ;
    (c) le fait de soumettre ledit sérum microfiltré à une étape de nanofiltration qui élimine les molécules ayant une taille supérieure à 35 nanomètres, en produisant ainsi un sérum nanofiltré ;
    (d) le fait de verser une aliquote dudit sérum nanofiltré dans un flacon, ledit sérum nanofiltré étant sous une forme destinée à une administration à un patient et comprenant le complexe stabilisé de CRH et d'alpha-2 macroglobuline ;
    le sérum restant non congelé à travers les étapes (b) à (d).
  2. Procédé selon la revendication 1, dans lequel le sérum est congelé après l'étape (d) et décongelé avant l'administration au patient, sous réserve toutefois que ledit sérum ne soit pas soumis à une étape de congélation ultérieure avant ladite administration au patient.
  3. Procédé selon la revendication 1 ou la revendication 2, dans lequel l'étape de nanofiltration est réalisée en utilisant un filtre de 35 nanomètres, par exemple en utilisant un filtre à fibres creuses de 35 nanomètres.
  4. Procédé selon l'une quelconque des revendications 1 à 3, comprenant en outre l'étape d'ajustement de la concentration finale en protéines jusqu'à 4-5 milligrammes de protéines par millilitre ; optionnellement dans lequel le sérum hyperimmun est congelé seulement après ledit ajustement de la concentration finale en protéines.
  5. Procédé selon l'une quelconque des revendications 1 à 4, dans lequel l'exposition à la température ambiante est strictement minimisée à tous les stades du procédé.
  6. Formulation comprenant un complexe stabilisé de CRH et d'alpha-2 macroglobuline, la formulation étant produite par le procédé selon l'une quelconque des revendications 1 à 5 ; la formulation comprenant optionnellement plus de 50 000 pg/ml d'alpha-2 macroglobuline.
  7. Formulation comprenant un complexe stabilisé d'hormone de libération de la corticotrophine (CRH) et d'alpha-2 macroglobuline, la formulation comprenant plus de 50 000 pg/ml d'alpha-2 macroglobuline.
  8. Formulation selon la revendication 6 ou la revendication 7, comprenant entre 100 000 pg/ml et 150 000 pg/ml d'alpha-2 macroglobuline ; la formulation comprenant optionnellement en outre 80-120 pg/ml de CRH ; la formulation comprenant optionnellement 90-110 pg/ml de CRH.
  9. Formulation selon l'une quelconque des revendications 6 à 8, dans laquelle la CRH est non humaine.
  10. Formulation selon l'une quelconque des revendications 6 à 9, comprenant en outre un ou plusieurs stabilisants ; lesdits un ou plusieurs stabilisants étant optionnellement sélectionnés parmi la fibronectine et l'albumine.
  11. Formulation selon l'une quelconque des revendications 6 à 10, comprenant en outre un peptide de proopiomélanocortine (POMC), optionnellement à une concentration d'au moins 140 pmol/l.
  12. Formulation selon la revendication 11, dans laquelle le peptide de POMC est non humain.
  13. Formulation selon l'une quelconque des revendications 6 à 12, comprenant en outre une ou plusieurs de la vasopressine, de l'ACTH, d'une MSH telle que l'alpha-MSH, la bêta-MSH, et la gamma-MSH, d'une LPH telle que la bêta-LPH et la gamma-LPH, de la bêta-endorphine, d'une enképhaline telle que la mét-enképhaline et la leu-enképhaline, du corticotropin-like peptide (CLIP), et de la lipotrophine gamma ; et comprenant optionnellement en outre la protéine de liaison de la CRH (CRH-BP).
  14. Formulation selon la revendication 13, comprenant moins de 50 pg/ml de CRH-BP.
  15. Formulation selon l'une quelconque des revendications 6 à 14, destinée à une utilisation dans la prévention ou le traitement d'une ou plusieurs pathologies sélectionnées parmi la maladie d'Alzheimer ; la sclérose systémique (SSc) ; la sclérose en plaques ; la polyarthrite rhumatoïde ; la névrite optique ; la maladie neuromotrice ; l'hépatite, en particulier l'hépatite C ; des maladies auto-immunes comprenant le lupus, le psoriasis, l'eczéma, la thyroïdite, et la polymyosite ; les lésions axonales ou nerveuses ; les cancers, en particulier les myélomes, les mélanomes, et les lymphomes ; les affections neurales, aussi bien avec démyélinisation que sans démyélinisation ; la maladie de Parkinson ; les affections inflammatoires ; l'obésité ; les troubles de la conduction nerveuse ; et les dysfonctionnements sexuels, en particulier le dysfonctionnement érectile.
EP13709511.3A 2012-06-25 2013-03-05 Formulation comprenant crh et l'alpha-2-macroglobuline Active EP2701728B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1211247.0A GB201211247D0 (en) 2012-06-25 2012-06-25 Improved formulation
GB201221741 2012-12-03
PCT/GB2013/050539 WO2014001749A1 (fr) 2012-06-25 2013-03-05 Formulation comprenant crh et l'alpha-2-immunoglobuline

Publications (2)

Publication Number Publication Date
EP2701728A1 EP2701728A1 (fr) 2014-03-05
EP2701728B1 true EP2701728B1 (fr) 2015-05-06

Family

ID=47884395

Family Applications (1)

Application Number Title Priority Date Filing Date
EP13709511.3A Active EP2701728B1 (fr) 2012-06-25 2013-03-05 Formulation comprenant crh et l'alpha-2-macroglobuline

Country Status (6)

Country Link
US (2) US20160206701A1 (fr)
EP (1) EP2701728B1 (fr)
AU (1) AU2013282995B2 (fr)
CA (1) CA2877562A1 (fr)
HK (1) HK1189349A1 (fr)
WO (1) WO2014001749A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201408171D0 (en) * 2014-05-08 2014-06-25 Aimsco Ltd Formulation and method of manufacture
US20170326166A1 (en) * 2014-10-17 2017-11-16 University Of Virginia Patent Foundation Compositions and methods for treating pituitary tumors
GB201501800D0 (en) * 2015-02-03 2015-03-18 Aimsco Ltd Treatment of medical conditions
FR3045669B1 (fr) 2015-12-16 2019-04-05 Laboratoires Expanscience Procedes d'evaluation des effets de la deshydratation sur la peau d'enfant
GB201617175D0 (en) * 2016-10-10 2016-11-23 Iconic Intellectual Property Limited Assay
GB201911064D0 (en) 2019-08-02 2019-09-18 Tarian Biologics Ltd Therapy
GB201911063D0 (en) 2019-08-02 2019-09-18 Tarian Biologics Ltd Formulations

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002317285B2 (en) 2001-07-02 2007-05-24 Aimsco Limited Use of polyclonal anti-HIV goat serum as a therapeutic agent
JP2005532261A (ja) 2002-01-28 2005-10-27 エイムスコ・リミテッド 治療
PL1708753T3 (pl) 2003-12-11 2010-07-30 Aimsco Ltd Zastosowanie surowicy koziej do leczenia weterynaryjnego
EP2184085B1 (fr) 2004-04-05 2014-11-05 Aimsco Limited Traitement des maladies
BRPI0513062A (pt) * 2004-07-08 2008-04-22 Aimsco Ltd composição farmacêutica, método de estimular a produção de pomc em um paciente, usos de um peptìdeo de crf isolado e de um peptìdeo de pomc isolado, e, métodos de tratamento para uma doença, de produzir crf e de tratamento curativo, melhorador ou profilático de uma doença
GB0415359D0 (en) * 2004-07-08 2004-08-11 Aimsco Ltd Medicament
GB0600202D0 (en) 2006-01-06 2006-02-15 Aimsco Ltd Treatment of HIV
EP2114437A2 (fr) * 2006-10-16 2009-11-11 ConjuChem Biotechnologies Inc. Peptides du facteur libérateur de corticotrophine modifiés et leurs utilisations

Also Published As

Publication number Publication date
HK1189349A1 (en) 2014-06-06
AU2013282995B2 (en) 2018-10-04
EP2701728A1 (fr) 2014-03-05
US20180221450A1 (en) 2018-08-09
AU2013282995A1 (en) 2015-01-22
CA2877562A1 (fr) 2014-01-03
WO2014001749A1 (fr) 2014-01-03
US20160206701A1 (en) 2016-07-21

Similar Documents

Publication Publication Date Title
US20180221450A1 (en) Formulation Comprising A Stabilized Complex Of Corticotropin Releasing Hormone And Alpha-2 Macroglobulin
AU2005276242B2 (en) Medicament
US20140072530A1 (en) Treatment of hiv
US8716215B2 (en) Method of treating or preventing tissue deterioration, injury or damage due to a neuro-, muscular- or neuro-muscular-degenerative disease, or restore tissue adversely affected by said disease
US20130203669A1 (en) Medicament
WO2015097460A1 (fr) Formulation améliorée
US20130344102A1 (en) Formulation
WO2015170122A1 (fr) Formulation et méthode de production de celle-ci
WO2021023977A1 (fr) Formulations comprenant de la corticolibérine (crh) et de l'alpha -2 macroglobuline

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20131106

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1189349

Country of ref document: HK

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 47/42 20060101ALI20140827BHEP

Ipc: A61K 38/22 20060101AFI20140827BHEP

Ipc: A61K 38/57 20060101ALI20140827BHEP

Ipc: A61P 31/14 20060101ALI20140827BHEP

Ipc: A61K 38/33 20060101ALI20140827BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20141016

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 725224

Country of ref document: AT

Kind code of ref document: T

Effective date: 20150615

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602013001707

Country of ref document: DE

Effective date: 20150618

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: SERVOPATENT GMBH, CH

REG Reference to a national code

Ref country code: NL

Ref legal event code: T3

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 725224

Country of ref document: AT

Kind code of ref document: T

Effective date: 20150506

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150506

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150907

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150806

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150506

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150506

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150506

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150806

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150506

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150506

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150506

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150807

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150906

REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1189349

Country of ref document: HK

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150506

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150506

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602013001707

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150506

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150506

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150506

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150506

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 4

26N No opposition filed

Effective date: 20160209

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150506

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150506

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150506

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150506

Ref country code: LU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160305

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150506

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150506

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 5

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150506

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150506

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20130305

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150506

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160331

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150506

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 6

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150506

REG Reference to a national code

Ref country code: CH

Ref legal event code: PCAR

Free format text: NEW ADDRESS: WANNERSTRASSE 9/1, 8045 ZUERICH (CH)

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 602013001707

Country of ref document: DE

Representative=s name: ZACCO LEGAL RECHTSANWALTSGESELLSCHAFT MBH, DE

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20230526

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20240325

Year of fee payment: 12

Ref country code: NL

Payment date: 20240322

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20240326

Year of fee payment: 12

Ref country code: GB

Payment date: 20240326

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20240325

Year of fee payment: 12